Pfizer buys Amplyx to expand drug-resistant treatment portfolio

  29 April 2021

Pfizer Inc said it has acquired privately-held Amplyx Pharmaceuticals, which is developing a new treatment for drug-resistant “superbug” fungal infections in patients with compromised immune systems.

If approved, Amplyx’s lead drug fosmanogepix would be the first new class of antifungal treatments in 20 years. Terms of the deal were not disclosed.

Fungi, like bacteria, can develop the ability to defeat the drugs designed to kill them.

Further reading: WHTC
Author(s): Julie Steenhuysen
Healthy Patients   Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University

Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!